Day Traders Tag icon

×
CollPlant Biotechnologies (NASDAQ: CLGN) and Stratasys Ltd. (NASDAQ: SSYS) recently announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer. The study is likely to focus on the ability of implants to grow natural breast tissue and completely degrade over time. As part of the study, 3D printed breast implants consisting of 200cc in the volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin printer are to be tested. The pre-clinical study marks a significant step forward in the companies' combined effort to provide patients with care using regenerative medicine instead of traditional implants. More on the News While CollPlant is a cutting-edge firm in regenerative and aesthetic medicine, creating innovative technologies and products based on its rhCollagen for tissue regeneration and organ production, Stratasys is a leader in polymer 3D printing solutions. Stratasys modified the Origin printer ...


In The news